1-(2-氨基吡啶-4-基)-2-(4-氟苯基)-乙酮 | 452056-80-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-氨基吡啶-4-基)-2-(4-氟苯基)-乙酮
• 英文名称: 1-(2-aminopyridin-4-yl)-2-(4-fluorophenyl)ethanone
• 英文别名: 1-(2-amino-pyridin-4-yl)-2-(4-fluoro-phenyl)-ethanone；2-(4-fluorophenyl)-1-(2-amino-4-pyridyl)ethanone
• CAS: 452056-80-3
• 化学式: C₁₃H₁₁FN₂O
• 分子量: 230.242
• InChiKey: IOXAEZSQRZMYNX-UHFFFAOYSA-N

物化性质

• 熔点：
  157.0℃
• 沸点：
  432.1±35.0 °C(Predicted)
• 密度：
  1.269±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2-氨基吡啶-4-基)-2-(4-氟苯基)-乙酮 在 盐酸 、 4-二甲氨基吡啶 、 2,2,4,4-四甲基-1,3-环丁烷二硫酮 、 sodium methylate 、 potassium carbonate 、 亚硝酸异戊酯 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 49.0h， 生成 4-(4-(4-fluorophenyl)-1-methyl-2-(methylthio)-1H-imidazol-5-yl)pyridin-2-amine
  参考文献：
  名称：

  Identification of Regioisomers in a Series of N-Substituted Pyridin-4-yl Imidazole Derivatives by Regiospecific Synthesis, GC/MS, and ¹H NMR

  摘要：

  The regiospecific synthesis of 2a (Scheme 3), a novel and potent pyridinyl imidazole inhibitor of p38 MAP (mitogen-activated protein) kinase, and the regioselective preparation of its regioisomer 2b (Scheme 4) are described. Chromatographic and spectroscopic data are presented, which in this class of compounds allow the unambiguous identification of regioisomers prepared by a nonregiospecific synthetic strategy. Biological data demonstrating the importance of the correct regiochemistry for inhibition of p38 are given.

  DOI：

  10.1021/jo026619w
• 作为产物：
  描述：

  2-(乙酰氨基)-4-甲基吡啶 在 potassium permanganate 、 氢溴酸 、 N,N'-羰基二咪唑 作用下， 以 水 为溶剂， 生成 1-(2-氨基吡啶-4-基)-2-(4-氟苯基)-乙酮
  参考文献：
  名称：

  Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases

  摘要：

  The anti-inflammatory potential of p38 mitogen-activated protein kinase (MAPK) inhibitors was coincidentally expanded to a dual inhibition of p38 alpha MAPK and phosphodiesterase 4 (PDE4), and the potential benefits arising from the blockage of both inflammation-related enzymes were thoroughly investigated. The most promising compound, CBS-3595 (1), was successively evaluated in in vitro experiments as well as in ex vivo and in vivo preclinical studies after administration of 1 to rodents, dogs, and monkeys. The resulting data clearly indicated a potent suppression of tumor necrosis factor alpha release. For reconfirming the findings of the animal studies when administering 1 to healthy human volunteers, a phase I clinical trial was conducted. Apart from further information regarding the pharmacokinetic and pharmacodynamic characteristics of 1, it was demonstrated that dual inhibition of p38 alpha MAPK and PDE4 is able to synergistically attenuate the excessive anti-inflammatory response.

  DOI：

  10.1021/acs.jmedchem.6b01647
• 作为试剂：
  描述：

  氢溴酸 、 N-[4-[(4-氟苯基)乙酰基]-2-吡啶基]乙酰胺 、 氨 在 ice 、 1-(2-氨基吡啶-4-基)-2-(4-氟苯基)-乙酮 、 petroleum ether 、 乙醚 作用下， 反应 30.0h， 生成 1-(2-氨基吡啶-4-基)-2-(4-氟苯基)-乙酮
  参考文献：
  名称：

  2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry

  摘要：

  本发明涉及公式I1中的2-硫代取代咪唑衍生物，其中基团R1，R2，R3和R4如描述中所定义。根据本发明的化合物具有免疫调节和/或细胞因子释放抑制作用，因此适用于治疗与免疫系统紊乱相关的疾病。

  公开号：

  US20040116416A1

文献信息

• Regiospecific and Highly Flexible Synthesis of 1,4,5-Trisubstituted 2-Sulfanylimidazoles from Structurally Diverse Ethanone Precursors
  作者：Stefan Laufer、Dominik Hauser、Andy Liedtke

  DOI：10.1055/s-2007-1000852

  日期：2008.1

  Imidazoles represent important bioactive scaffolds in medicinal chemistry. More than 2,500 structures are listed in drug discovery databases and over 3,000 patents have been claimed for imidazole-based structures. Recent imidazole pharmacophores have targeted various MAP kinases. p38 Mitogen-activated protein (MAP) kinase plays a central role in the signaling network responsible for the upregulation of proinflammatory cytokines like IL-1β and TNFα and offers, therefore, a valid target for small molecule anti-inflammatory drugs. 2-Sulfanylimidazole derivatives offer some advantages over prototype inhibitors (SB203580), e.g. lower cytochrom P450 interactions and better kinetic properties. We report here three novel regioselective and, at the same time, highly flexible synthetic approaches towards 1,4,5-trisubstituted 2-sulfanylimidazoles starting from different ethanone regioisomers allowing maximum variability of all substituents introduced. As a result, a variety of selective and highly potent p38 MAPK inhibitors were prepared and selected for further preclinical development. Synthesis of structurally diverse inhibitor candidates, p38 inhibition data, and selectivity profiling of some selected compounds are specified. Furthermore, the benefits of the useful, brief synthetic sequences are outlined and contrasted with already published multistep routes.

  咪唑类是药物化学中重要的生物活性骨架。药物发现数据库中列出了超过2,500种结构，并且已有超过3,000项专利针对咪唑类结构提出申请。最近的咪唑类药效团主要针对各种MAP激酶。p38丝裂原活化蛋白（MAP）激酶在信号网络中起着核心作用，该网络负责上调如IL-1β和TNFα等促炎细胞因子，因此，它为小分子抗炎药物提供了有效的靶点。2-巯基咪唑衍生物相较于原型抑制剂（如SB203580）具有一些优势，例如较低的细胞色素P450相互作用和更好的动力学特性。我们在此报告了三种新颖的区域选择性且高度灵活的合成方法，这些方法从不同的乙酮区域异构体出发，实现了对所有引入取代基的最大可变性，从而合成了1,4,5-三取代的2-巯基咪唑。由此，制备并筛选出一系列选择性强且高效的p38 MAPK抑制剂，用于进一步的临床前开发。详细描述了结构多样化的抑制剂候选物的合成、p38抑制数据以及部分精选化合物的选择性分析。此外，还概述了简短合成序列的优点，并与已发表的多步骤路线进行了对比。
• Imidazole compounds having an antiinflammatory effect
  申请人：MERCKLE GMBH

  公开号：EP1894925A1

  公开（公告）日：2008-03-05

  The invention relates to 2-sulfinyl- or 2-sulfonyl-substituted imidazole derivatives of the formula I in which the radicals R1, R2, R3 and R4 have the meaning indicated in the description. The compounds of the invention have an immunomodulating and/or cytokine release-inhibiting effect and are therefore suitable for the treatment of disorders associated with an impairment of the immune system.

  这项发明涉及公式I的2-磺酰基或2-磺酰基取代的咪唑衍生物， 其中基团R1、R2、R3和R4具有描述中指示的含义。该发明的化合物具有免疫调节和/或细胞因子释放抑制作用，因此适用于治疗与免疫系统功能障碍相关的疾病。
• IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT
  申请人：Albrecht Wolfgang

  公开号：US20100069436A1

  公开（公告）日：2010-03-18

  The invention relates to imidazole derivatives of the Formula (I) in which the radicals R 1 , R 2 , R 3 , R 4 and R 5 have the meanings indicated in the description. The compounds of the invention have an immunomodulating and/or cytokine release-inhibiting effect and are therefore suitable for the treatment of disorders associated with an impairment of the immune system.

  本发明涉及式（I）的咪唑衍生物，其中基团R1、R2、R3、R4和R5具有说明书中指示的含义。该发明的化合物具有免疫调节和/或细胞因子释放抑制作用，因此适用于治疗与免疫系统受损有关的疾病。
• 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS
  申请人：Albrecht Wolfgang

  公开号：US20100273833A1

  公开（公告）日：2010-10-28

  The invention relates to 2-sulfinyl- or 2-sulfonyl-substituted imidazole derivatives of the formula (I) in which the radicals R 1 , R 2 , R 3 and R 4 have the meaning indicated in the description. The compounds of the invention have an immunomodulating and/or cytokine release-inhibiting effect and are therefore suitable for the treatment of disorders associated with an impairment of the immune system.

  本发明涉及式(I)的2-亚磺酰基或2-磺酰基取代的咪唑衍生物，其中基团R1、R2、R3和R4的含义如说明书所示。本发明的化合物具有免疫调节和/或细胞因子释放抑制作用，因此适用于治疗与免疫系统损伤有关的疾病。
• Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors
  作者：Stefan Laufer、Dominik Hauser、Thomas Stegmiller、Claudia Bracht、Kathrin Ruff、Verena Schattel、Wolfgang Albrecht、Pierre Koch

  DOI：10.1016/j.bmcl.2010.09.012

  日期：2010.11

  The synthesis of 2,4,5-trisubstituted and 1,2,4,5-tetrasubstituted imidazoles as potent p38 alpha mitogen-activated protein kinase inhibitors is described. The trisubstituted imidazole series was found to be more potent than the tetrasubstituted imidazole series. Many of these compounds show low-nanomolar activities in the isolated p38 alpha MAP kinase inhibition assay. The structure-activity relationships between these two series are different and not comparable. (C) 2010 Elsevier Ltd. All rights reserved.